Immunotherapy for Liver Cancer Before Transplant
What You Need to Know Before You Apply
What is the purpose of this trial?
Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.
Who Is on the Research Team?
Davendra P. Sohal
Principal Investigator
University of Cincinnati
Are You a Good Fit for This Trial?
This trial is for adults over 18 with hepatocellular carcinoma (HCC) who haven't had prior HCC therapy, are listed for a liver transplant, and meet specific health criteria including a Child-Pugh Score of 5-7. They must have tumors within certain size limits, no extrahepatic disease or severe autoimmune disorders, and be able to follow the study protocol.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive durvalumab and tremelimumab for up to 4 months
Washout
A minimum 28-day washout period before locoregional therapy
Locoregional Therapy
Participants undergo locoregional therapy per institutional standards
Pre-Transplant Washout
A minimum 72-day washout period from the end of immunotherapy before liver transplant
Liver Transplant
Participants undergo liver transplant
Follow-up
Participants are monitored for safety and effectiveness after transplant
Long-term Follow-up
Survival follow-up will continue for 5 years after the end of treatment
What Are the Treatments Tested in This Trial?
Interventions
- Durvalumab
- Liver Transplant
- Tremelimumab
Durvalumab is already approved in European Union, United States, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Davendra Sohal
Lead Sponsor